Fen-Phen Side Effects Could Result In Primary Pulmonary Hypertension Lawsuits
Fen Phen or Pondimin (Generic: Fenfluramine) and (Generic: Dexfenfluramine), has been linked to Heart Valve Disease and Primary Pulmonary Hypertension (PPH). Fen Phen was a popular appetite suppressant drug prescribed to people wishing to lose weight.
Final Fen-Phen Deadlines
The deadline to file for Matrix level Fen-Phen claims is December 31, 2015. After this date, Fen-Phen/Redux cases will come to an end.
When the $3.75 billion settlement was given final approval in 2002, the settlement established a fund to compensate Class Members who filed claims over injuries allegedly caused by the weight loss drug. A scientifically established "matrix" is used to evaluate valvular heart conditions that may be caused by Fen-Phen and claimants may file different Matrix-level claims based on the type of condition they experienced.
Fen-Phen has been widely withdrawn and essentially became an infamous weight loss drug in the years since it was pulled from the market. The product drew scrutiny from the public and from the healthcare community after it was shown to cause potentially life threatening heart valve and hypertension problems. Users have reported suffering from chronic ailments after taking the drug, such as heart palpitations, heart valve problems, pulmonary hypertension, shortness of breath, and chronic fatigue, among other issues.
Withdrawal from the Market
In 1997, the FDA asked Wyeth-Ayerst Laboratories (American Home Products) the makers of Pondimin (Fenfluramine) and Redux (Dexfenfluramine), to withdraw its popular anti-obesity drugs from the market. American Home Products Corp. of Madison, N.J. manufactured fenfluramine under the brand name Pondimin. An American Home Products subsidiary Wyeth-Ayerst Laboratories manufactured Dexfenfluramine for Interneuron Pharmaceuticals under the name of Redux. Medical studies have linked Pondimin or Redux to heart valve disease.
|Quick Facts: Fen Phen Reference Guide|
|Manufacturer||American Home Products|
|Approved Uses||Appetite suppressant|
|Serious Side Effects||PPH
Heart valve disease
|Related Topics||Heart Valve Disease
The FDA stated that in findings from doctors who evaluated patients taking Fenfluramine and Dexfenfluramine with echo-cardiograms, approximately 30 percent of patients had abnormal echo-cardiograms, even though they had no symptoms. This is a much higher than expected percentage of abnormal test results. Additionally, a Mayo Clinic study that was published in the New England Journal of Medicine on August 28, 1997 suggested that as high as one-third of a patient sampling of Fen-Phen diet pill users had evidence of heart valve disease. The study found that there was a high incidence of heart valve disease in patients taking these diet pills, without any other known reason for valve disease. In addition to heart valve disease, the use of Fenfluramine and Dexfenfluramine has been found to increase the risk of developing Primary Pulmonary Hypertension or (PPH). PPH is a rare disease of that causes the progressive narrowing of the blood vessels of the lungs. Studies estimate that treatment with certain appetite suppressant drugs tends to increase the chances of developing PPH by approximately 25 to 30%.